Search the Epitope Variant and Escape Mutation Database

Help

Found 3 matching records:

Displaying record number 55763

HXB2 Location Gag(77-85) Gag Epitope Map
View variants at this location

SLYNTVATL

`SLfNTVATL`		susceptible form
`SLYNlVATL`		susceptible form
`SLfNlVATL`		susceptible form
`SiYNlVATL`		susceptible form

Epitope Name SL9

Species (MHC/HLA) human, transgenic mouse(A2)

Variant Details

Showing all: 4 variant(s).

Variant ID.	`76`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNTVATL`
Mutations	Y/F
Epitope Location	Y3F
HXB2 Location	Y79F
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.

Variant ID.	`77`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNlVATL`
Mutations	T/L
Epitope Location	T5L
HXB2 Location	T81L
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.

Variant ID.	`78`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNlVATL`
Mutations	Y/F T/L
Epitope Location	Y3F T5L
HXB2 Location	Y79F T81L
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.

Variant ID.	`79`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SiYNlVATL`
Mutations	L/I T/L
Epitope Location	L2I T5L
HXB2 Location	L78I T81L
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.

References

Blondelle2008 Sylvie E. Blondelle, Rosa Moya-Castro, Keiko Osawa, Kim Schroder, and Darcy B. Wilson. Immunogenically Optimized Peptides Derived from Natural Mutants of HIV CTL Epitopes and Peptide Combinatorial Libraries. Biopolymers, 90(5):683-694, 2008. PubMed ID: 18481808. Show all entries for this paper.

Displaying record number 56141

HXB2 Location Gag(151-159) Gag Epitope Map
View variants at this location

Epitope

TLNAWVKVV

Epitope Alignment

Variants

`TLNAWVKVi`		diminished response
`TLNAWVKaV`		susceptible form
`TLNAWVKai`		susceptible form

Epitope Name TV9

Species (MHC/HLA) human, transgenic mouse(A2)

Variant Details

Showing all: 3 variant(s).

Variant ID.	`80`
Epitope Seq.	`TLNAWVKVV`
Variant Seq.	`TLNAWVKVi`
Mutations	V/I
Epitope Location	V9I
HXB2 Location	V159I
Mutation Type	DR: diminished response
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.

Variant ID.	`81`
Epitope Seq.	`TLNAWVKVV`
Variant Seq.	`TLNAWVKaV`
Mutations	V/A
Epitope Location	V8A
HXB2 Location	V158A
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.

Variant ID.	`82`
Epitope Seq.	`TLNAWVKVV`
Variant Seq.	`TLNAWVKai`
Mutations	V/A V/I
Epitope Location	V8A V9I
HXB2 Location	V158A V159I
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.

References

Displaying record number 56140

HXB2 Location Pol(464-472) Pol Epitope Map
View variants at this location

Epitope

ILKEPVHGV

Epitope Alignment

Variants

`ILKdPVHGV`		diminished response
`ILKEPVHrV`		susceptible form
`ILrEPiHGV`		susceptible form
`ILKEPVHGi`		susceptible form

Epitope Name IV9

Species (MHC/HLA) human, transgenic mouse(A2)

Variant Details

Showing all: 4 variant(s).

Variant ID.	`83`
Epitope Seq.	`ILKEPVHGV`
Variant Seq.	`ILKdPVHGV`
Mutations	E/D
Epitope Location	E4D
HXB2 Location	E467D
Mutation Type	DR: diminished response
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of IV9 were tested in transgenic mice. Mutants of epitope IV9 when tested in transgenic mice, showed that the consensus was strongly immunogenic, but the most common mutant, ILKdPVHGV was not especially immunogenic or cross-reactive. Rare mutant, ILKEPVHrV, was highly immunogenic, and cross-reactive to the consensus. Sequences ILrEPiHGV and ILKEPVHGi were also cross-reactive to the consensus.

Variant ID.	`84`
Epitope Seq.	`ILKEPVHGV`
Variant Seq.	`ILKEPVHrV`
Mutations	G/R
Epitope Location	G8R
HXB2 Location	G471R
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of IV9 were tested in transgenic mice. Mutants of epitope IV9 when tested in transgenic mice, showed that the consensus was strongly immunogenic, but the most common mutant, ILKdPVHGV was not especially immunogenic or cross-reactive. Rare mutant, ILKEPVHrV, was highly immunogenic, and cross-reactive to the consensus. Sequences ILrEPiHGV and ILKEPVHGi were also cross-reactive to the consensus.

Variant ID.	`85`
Epitope Seq.	`ILKEPVHGV`
Variant Seq.	`ILrEPiHGV`
Mutations	K/R V/I
Epitope Location	K3R V6I
HXB2 Location	K466R V469I
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of IV9 were tested in transgenic mice. Mutants of epitope IV9 when tested in transgenic mice, showed that the consensus was strongly immunogenic, but the most common mutant, ILKdPVHGV was not especially immunogenic or cross-reactive. Rare mutant, ILKEPVHrV, was highly immunogenic, and cross-reactive to the consensus. Sequences ILrEPiHGV and ILKEPVHGi were also cross-reactive to the consensus.

Variant ID.	`86`
Epitope Seq.	`ILKEPVHGV`
Variant Seq.	`ILKEPVHGi`
Mutations	V/I
Epitope Location	V9I
HXB2 Location	V472I
Mutation Type	SF: susceptible form
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay
Note	To identify immunogenically optimized epitopes for use in vaccines, mutants of IV9 were tested in transgenic mice. Mutants of epitope IV9 when tested in transgenic mice, showed that the consensus was strongly immunogenic, but the most common mutant, ILKdPVHGV was not especially immunogenic or cross-reactive. Rare mutant, ILKEPVHrV, was highly immunogenic, and cross-reactive to the consensus. Sequences ILrEPiHGV and ILKEPVHGi were also cross-reactive to the consensus.